Additional Research Directions & Literature Analysis
This document presents five additional approaches discovered during extended literature research. These are supplementary ideas to the main DHP-Paliperidone prodrug proposal and are ordered by priority and feasibility.
The pivot from piperidine-N conjugation to paliperidone-9-OH ester is chemically correct. Two main risks remain:
| # | Problem | Severity |
|---|---|---|
| 1 | Ester hydrolysis by plasma esterases — premature release before BBB passage | HIGH |
| 2 | P-gp recognition unchanged — piperidine-N remains unmodified | MODERATE |
Current literature (Rautio et al. 2025, RSC Med Chem; Huttunen 2018, Bioorg Med Chem Lett) consistently shows:
Instead of: Paliperidone-9-O-CO-DHP (ester)
Better: Paliperidone-9-O-CO-NH-DHP (carbamate)
Advantages:
Challenge: Paliperidone has a 9-OH group (alcohol), not an amine → classical carbamate needs an amine. Solution: Reversed carbamate — DHP-3-NH as amine component, paliperidone-9-OH as alcohol component → carbonate or mixed carbamate/carbonate. Alternative: carbonate linker (R-O-CO-O-R') as a compromise between ester and carbamate stability.
| Aspect | Assessment |
|---|---|
| Plasma stability improvement | Risk ↓ from 3 to 1–2 |
| Synthesis complexity | Slightly increased, but feasible |
| Net effect | Significant improvement |
This is a potentially transformative insight for the project:
Bolognesi and colleagues converted the piperidine ring itself of donepezil (also a piperidine-containing CNS drug) into a 1,4-dihydropyridine ring. The DHP form is the prodrug; the oxidized pyridinium form is the active compound.
Results:
The concept: Convert risperidone's piperidine ring ITSELF into the DHP/pyridinium system.
Critical question: Does a risperidone-pyridinium analogue retain D2 affinity?
Analysis based on D2 crystal structure (Wang et al., Nature 2018, PDB: 6CM4):
Prognosis: D2 affinity would likely be significantly altered (probably reduced), but a permanent positive charge can still engage in ionic interaction with Asp114, and there are precedents for positively charged D2 ligands.
RECOMMENDATION: This would be a simple and cheap in-silico test: Docking study of risperidone-pyridinium vs. risperidone in the D2 crystal structure (6CM4). If affinity is retained → completely new, elegant approach without the 9-OH linker problem.
Bohn, Chmielewski & Hrycyna (Purdue University) developed paliperidone prodrug dimers that inhibit both P-gp and ABCG2. Quetiapine dimers showed >80-fold better P-gp inhibition than monomeric quetiapine.
Concept: Instead of a single DHP-paliperidone molecule, a dimeric architecture with two paliperidone units connected via a DHP-containing linker. The dimer inhibits P-gp during transit → less efflux. After oxidation to pyridinium: trapping + slow release of 2× paliperidone.
Assessment: Intellectually interesting but practically too complex for Phase 1 (high MW ~900+ Da, complex synthesis, novel regulatory path). Could serve as Plan B.
Recent works (2024–2025) show "rotamer-controlled" and "self-immolative" linkers that circulate stably in plasma and are released by specific triggers (pH, enzymes, redox) in target tissue.
Application: Instead of direct ester/carbamate binding DHP→paliperidone, use a self-immolative spacer. Trigger: The DHP→pyridinium oxidation ITSELF changes the electronic environment → triggers the self-immolative cascade → releases paliperidone.
Advantage: The oxidation (= lock-in signal) is directly coupled to drug release. Elegant mechanistic connection.
Challenge: Additional synthesis complexity; requires experimental validation.
If the carbamate route introduces synthetic complications, a simpler approach exists:
Advantage: Simplest synthetic modification; well-documented in literature.
Limitation: Incremental improvement, does not address the P-gp problem.
| Priority | Idea | Effort | Potential | Next Step |
|---|---|---|---|---|
| 1 | Carbonate/carbamate instead of ester | Low | High — solves Problem #1 | RDKit: LogP/TPSA/MW calculation; sketch synthesis route |
| 2 | Pyridinium-risperidone docking | Very low | Potentially transformative | Molecular docking in D2 (6CM4) — 1 day of work |
| 3 | Sterically hindered ester | Low | Moderate | Compare with standard ester in plasma stability assay |
| 4 | Self-immolative linker | Medium | High but speculative | Read concept papers; discuss with synthetic chemist |
| 5 | Dimer strategy | High | Moderate | Only as Plan B if approaches 1–3 fail |
| Reference | Relevance |
|---|---|
| Namdeo (2025), Expert Opin Drug Deliv 22:805–822 | Most current review of DHP-CDS system; confirms platform validity |
| Lillethorup, Hemmingsen & Qvortrup (2025), RSC Med Chem (PMC11740913) | Most comprehensive mechanistic review; covers DHP lock-in and donepezil example |
| Bolognesi et al. (2017), J Med Chem 60:7495 | Direct precedent for piperidine→DHP transformation |
| Bohn et al. (2017), Mol Pharm 14:1107 | P-gp/ABCG2 dual inhibition with paliperidone dimers |
| Wang et al. (2018), Nature 555:269 — PDB: 6CM4 | D2-risperidone crystal structure — basis for docking study |
| Rotamer-controlled SI linkers (2025), ACS Med Chem Lett | Latest SI linker technology for CNS prodrugs |
This document supplements the main Brain-Selective Risperidone Prodrug Research Proposal. It contains additional research directions and does not modify the existing analysis. — Marko Leicht, Independent Researcher, Obertrubach, Germany